Navigation Links
Affitech and Omeros Enter Into Antibody Discovery and Development Agreement

SEATTLE and OSLO, Norway, Aug. 19 /PRNewswire/ -- Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, and Affitech AS, a Norwegian human antibody therapeutics company, today announced that they have entered into an agreement for the discovery and development of fully human antibodies for Omeros' MASP-2 program. MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection and cardiovascular and renal ischemia-reperfusion injury.

"This agreement marks an important milestone in our MASP-2 program, and ensures that Omeros can access high-affinity, fully human antibodies against MASP-2," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "We are impressed by Affitech's technology, track record and personnel, and look forward to our collaboration."

Under this collaboration, Omeros, based on its exclusive intellectual property position, will continue to advance the development of its MASP-2 program. Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen(TM) platform and engineering methods, to generate fully human MASP-2 antibodies for Omeros. Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros. No further terms of the agreement were disclosed.

"We are excited about this collaboration with Omeros," said Martin Welschof, Ph.D., CEO of Affitech. "Omeros' proprietary MASP-2 program is focused on a target with broad commercial applications, and provides Affitech the opportunity to apply our expertise, human antibody library and screening platform to a non-cancer disease field. We believe that our proven technology, together with Omeros' intellectual property position and development capabilities, can yield a new and clinically important class of anti-inflammatory therapeutics."

About MASP-2

Mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target, is involved in the activation of the complement system. The complement system plays a role in the inflammatory response and becomes activated as a result of tissue damage (e.g., trauma) or infection by microbial pathogens. MASP-2 appears to be unique to, and required for the function of, a principal complement activation pathway, known as the lectin pathway. Importantly, inhibition of MASP-2 does not appear to interfere with the antibody-dependent classical complement activation pathway, a critical component of the acquired immune response to infection, and its abnormal function is associated with a wide range of autoimmune disorders. Omeros holds worldwide exclusive licenses to rights related to MASP-2, the antibodies targeting MASP-2 and the therapeutic applications for those antibodies from the University of Leicester and from its collaborator, Medical Research Council at Oxford University.

Notes to editors:

About Affitech AS

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company's proprietary product candidates currently in development were generated by CBAS(TM). Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as Roche, Peregrine, XOMA, Viventia, Dyax, Micromet, Pharmexa and others. Further information is available at

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at

SOURCE Affitech AS; Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
5. Chromos enters into an Arrangement Agreement
6. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
7. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
10. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
11. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
Post Your Comments:
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. (OTCQX: ... nutritional ingredients that creates science-based solutions for dietary ... and pharmaceutical products, today announced that the October ... and Founder, is now available for on-demand viewing ... -->   --> ...
(Date:10/7/2015)... , Oct. 7, 2015   PDI , ... released an infographic that highlights key challenges across various ... appropriate disinfectant for the situation. This tool is part ... hospitals can take to create efficiencies and lower healthcare-associated ... The visual guide emphasizes examples of how to use ...
(Date:10/7/2015)...   VWR (NASDAQ: VWR ), ... services and solutions, announced today that it has ... company that performs high volume purification of selected ... growing laboratory and production chemical manufacturing portfolio to ... Manuel Brocke-Benz , President and CEO ...
(Date:10/7/2015)... ... 07, 2015 , ... Park Systems , world-leader in ... provide a comprehensive overview of the innovations in smart coatings using nanoparticle additives ... This webinar will be given by Professor Roberto Advincula, professor with the Department ...
Breaking Biology Technology:
... Nov. 28 On Monday, December 1, 2008, at,8:30 ... Therapeutics, Inc.,s (CTI) (Nasdaq and MTA: CTIC) management team ... Spectrum Pharmaceuticals,of Irvine, California to jointly market and develop ... Call Numbers, Monday, December 1, ...
... today that it is refocusing all projects and priorities around ... be seen as a,consequence of the negative recommendation of the ... 2008 regarding the,approval of Iclaprim in the U.S. , ... FDA advisory board,s recommendation the Arpida,board intends to put the ...
... house always looking good, without cleaning or giving it ... with paint that can maintain itself and get rid ... process for producing photo-catalytic, self-cleaning coatings has been developed ... and Research), and licensed to Haruna (S) Pte Ltd. ...
Cached Biology Technology:
(Date:9/24/2015)... YORK , Sept. 24, 2015  EyeLock LLC, ... be showcasing its award winning and latest technology in ... Anaheim, California . EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/10/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces that the San ... will feature the Wocket® smart wallet for the first ... Touch Of Modern is an online retailer ... its 7.2 million members. Customers are affluent, urban influencers ...
Breaking Biology News(10 mins):
... and their colleagues in Japan are conducting research that may ... necessary step if man someday hopes to build molecular machines ... Dr. Eric Blough, a member of the research ... Biological Sciences, said his group has shown how bionanomotors can ...
... Biologists have known for long that ecology, the interaction ... in forming new species and in modifying living ones. ... The environment defines a template and the process of ... template. Some specialized theory, a few ...
... plant virus lures aphids to infected plants by making the ... they quickly leave for tastier, healthier ones. In the process, ... entomologists. "The virus improves the cues that insects use to ... is already in the plant," said Mark C. Mescher, assistant ...
Cached Biology News: